Antiinflammatory Medicinal Plants from the Ugandan Greater Mpigi Region Act as Potent Inhibitors in the COX-2/PGH2 Pathway
Open Access
- 12 February 2021
- Vol. 10 (2), 351
- https://doi.org/10.3390/plants10020351
Abstract
Our study investigates 16 medicinal plants via assessment of inhibition of proinflammatory enzymes such as cyclooxygenases (COX). The plants are used by traditional healers in the Greater Mpigi region in Uganda to treat inflammation and related disorders. We present results of diverse in vitro experiments performed with 76 different plant extracts, namely, (1) selective COX-2 and COX-1 inhibitor screening; (2) 15-LOX inhibition screening; (3) antibacterial resazurin assay against multidrug-resistant Staphylococcus aureus, Listeria innocua, Listeria monocytogenes, and Escherichia coli K12; (4) DPPH assay for antioxidant activity; and (5) determination of the total phenolic content (TPC). Results showed a high correlation between traditional use and pharmacological activity, e.g., extracts of 15 out of the 16 plant species displayed significant selective COX-2 inhibition activity in the PGH2 pathway. The most active COX-2 inhibitors (IC50 < 20 µg/mL) were nine extracts from Leucas calostachys, Solanum aculeastrum, Sesamum calycinum subsp. angustifolium, Plectranthus hadiensis, Morella kandtiana, Zanthoxylum chalybeum, and Warburgia ugandensis. There was no counteractivity between COX-2 and 15-LOX inhibition in these nine extracts. The ethyl acetate extract of Leucas calostachys showed the lowest IC50 value with 0.66 µg/mL (COX-2), as well as the most promising selectivity ratio with 0.1 (COX-2/COX-1). The TPCs and the EC50 values for DPPH radical scavenging activity showed no correlation with COX-2 inhibitory activity. This led to the assumption that the mechanisms of action are most likely not based on scavenging of reactive oxygen species and antioxidant activities. The diethyl ether extract of Harungana madagascariensis stem bark displayed the highest growth inhibition activity against S. aureus (MIC value: 13 µg/mL), L. innocua (MIC value: 40 µg/mL), and L. monocytogenes (MIC value: 150 µg/mL). This study provides further evidence for the therapeutic use of the previously identified plants used medicinally in the Greater Mpigi region.Keywords
Funding Information
- Bundesministerium für Bildung und Forschung (13FH026IX5, 13FH066PX5)
- Deutsche Forschungsgemeinschaft (414051096)
This publication has 110 references indexed in Scilit:
- 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?Cancer and Metastasis Reviews, 2011
- Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammationPharmacological Research, 2010
- Molecular basis of cyclooxygenase enzymes (COXs) selective inhibitionProceedings of the National Academy of Sciences of the United States of America, 2010
- Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell CarcinomaCancer Prevention Research, 2009
- Cyclooxygenases: structural and functional insightsJournal of Lipid Research, 2009
- Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicalsMethods, 2007
- Resolution of in flammation: state of the art, definitions and termsThe FASEB Journal, 2007
- NSAID-Associated Adverse Effects and Acid Control Aids to Prevent ThemDrug Safety, 2006
- Antioxidant activity of anti-inflammatory plant extractsLife Sciences, 2002
- Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapyBritish Journal of Pharmacology, 1999